Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy
J. Clin. Invest. Ilona Hauber, et al. 115:76 doi:10.1172/JCI21949 [
Go to this article.]
Figure 3Inhibition of clinical HIV-1 isolates. PBMCs from HIV-1–infected patients were cultured in the presence of CNI-1493. The culture medium was changed every 3 days. Every week, each culture was split 1:1, and fresh feeder PBMCs from 4 healthy donors, treated with PHA-P (6 μg/ml phytohemagglutinin) and PB (1 μg/μl polybrene) and preincubated in CNI-1493 for 4 days, were added along with recombinant IL-2. At day 14, cell counts, cell viability, and p24 antigen and/or bDNA levels were determined (cell counts ranged from 0.9 × 10
6 to 1.1 × 10
6 cells per milliliter; in all cultures tested, at least 80% of the cells were viable). The percentage of inhibition of virus replication as compared with replication in the respective untreated patient cells is shown.
